Medical management of older patients with lung cancer

Author:

Zenke Yoshitaka1ORCID,Hakozaki Taiki2,Nakahara Yoshiro3,Horinouchi Hidehito4ORCID,Ohe Yuichiro4ORCID,Barber Joe,

Affiliation:

1. Department of Thoracic Oncology, National Cancer Center Hospital East , Kashiwa , Japan

2. Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital , Tokyo , Japan

3. Department of Respiratory Medicine, Kitasato University School of Medicine , Kanagawa , Japan

4. Department of Thoracic Oncology, National Cancer Center Hospital , Tokyo , Japan

Abstract

Abstract Lung cancer is the most common cause of cancer-related death globally. In addition, its incidence increases with age, with approximately half of all cases diagnosed in patients aged ≥70. Molecular targeted therapies and immunotherapies for advanced non-small-cell lung cancer have markedly improved outcomes over the past two decades. Despite the high incidence of lung cancer in older people, most trials excluded such patients from enrollment. Therefore, the optimal treatment strategies for older patients remain unclear. The present review summarizes the published literature and provides guidance on the treatment of older patients with lung cancer within three broad stages: (i) early-stage lung cancer, (ii) locally advanced lung cancer and (iii) metastatic lung cancer. We also discuss the use of the latest evidence for older patients.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Geriatric oncology in the most aged societies;Japanese Journal of Clinical Oncology;2024-07-22

2. Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung Cancer;JAMA Oncology;2024-04-01

3. Message from the Editor-in-Chief;Japanese Journal of Clinical Oncology;2024-01

4. Message from the Editor-in-Chief;Japanese Journal of Clinical Oncology;2023-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3